Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Mixed Dyslipidemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H2 2014', provides an overview of the Mixed Dyslipidemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mixed Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mixed Dyslipidemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Mixed Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mixed Dyslipidemia Overview 6 Therapeutics Development 7 Pipeline Products for Mixed Dyslipidemia - Overview 7 Pipeline Products for Mixed Dyslipidemia - Comparative Analysis 8 Mixed Dyslipidemia - Therapeutics under Development by Companies 9 Mixed Dyslipidemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Mixed Dyslipidemia - Products under Development by Companies 13 Mixed Dyslipidemia - Companies Involved in Therapeutics Development 14 Amgen Inc. 14 CymaBay Therapeutics, Inc. 15 Intas Pharmaceuticals Ltd. 16 Novartis AG 17 Pfizer Inc. 18 Mixed Dyslipidemia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 bococizumab - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 evolocumab - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 INSUPR-001 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 MAT-9001 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 MBX-8025 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 TAP-311 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Mixed Dyslipidemia - Recent Pipeline Updates 36 Mixed Dyslipidemia - Dormant Projects 45 Mixed Dyslipidemia - Discontinued Products 46 Mixed Dyslipidemia - Product Development Milestones 47 Featured News & Press Releases 47 Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 47 Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol 50 Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 56 Disclaimer 56
List of Tables Number of Products under Development for Mixed Dyslipidemia, H2 2014 7 Number of Products under Development for Mixed Dyslipidemia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Mixed Dyslipidemia - Pipeline by Amgen Inc., H2 2014 14 Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2014 15 Mixed Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 16 Mixed Dyslipidemia - Pipeline by Novartis AG, H2 2014 17 Mixed Dyslipidemia - Pipeline by Pfizer Inc., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2014 36 Mixed Dyslipidemia - Dormant Projects, H2 2014 45 Mixed Dyslipidemia - Discontinued Products, H2 2014 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
